Seqirus begins shipping 2018-2019 influenza vaccines
Seqirus has started to ship its portfolio of more than 50 million doses of influenza vaccines to the United States in preparation for the upcoming 2018-2019 influenza season, the company announced Wednesday.
The company will provide Fluad influenza vaccine, adjuvanted, which it said is the only adjuvanted seasonal influenza vaccine specifically developed for people ages 65 years and older, as well as Flucelvax Quadrivalent influenza vaccine, available for those aged four and older, according to the company.
The Seqirus 2018-2019 influenza vaccine portfolio also includes Afluria Quadrivalent, an egg-based quadrivalent influenza vaccine, and Rapivab (peramivir injection), which the company said was the first-and-only one-dose intravenous antiviral treatment for acute uncomplicated influenza.
The company will provide Fluad influenza vaccine, adjuvanted, which it said is the only adjuvanted seasonal influenza vaccine specifically developed for people ages 65 years and older, as well as Flucelvax Quadrivalent influenza vaccine, available for those aged four and older, according to the company.
The Seqirus 2018-2019 influenza vaccine portfolio also includes Afluria Quadrivalent, an egg-based quadrivalent influenza vaccine, and Rapivab (peramivir injection), which the company said was the first-and-only one-dose intravenous antiviral treatment for acute uncomplicated influenza.